BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Verzenio (Abemaciclib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Verzenio (Abemaciclib)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07818967-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Verzenio (Abemaciclib): Phase 1 readout est. (NCT07818967)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1.\nStudy: A Study of Abemacicli
 b (LY2835219) in Healthy Participants\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 18967
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05305924-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05305924)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-P
 ositive\, Her2-Negative Metastatic Breast Cancer\nEstimated primary comple
 tion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05305924
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04393285-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04393285)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Abemaciclib and Letro
 zole to Treat Endometrial Cancer\nEstimated primary completion: 1 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT043932
 85
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Open-Label Umbrella Study To Evaluate Safety And Efficac
 y Of Elacestrant In Various Combination In Participants With Metastatic Br
 east Cancer\nEstimated primary completion: 27 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714072-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Verzenio (Abemaciclib): Phase 1 readout est. (NCT05714072)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1.\nStudy: A Study of Ruxolitini
 b in Combination With Abemaciclib for the Treatment of Myelofibrosis\nEsti
 mated primary completion: January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05714072
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03310879-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT03310879)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Study of the CDK4/6 I
 nhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Gene
 s Encoding D-Type Cyclins or Amplification of CDK4 or CDK6\nEstimated prim
 ary completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT03310879
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207734-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06207734)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Discontinuation of CDK4/6 Inhibitors in Patients With Meta
 static HR Positive\, HER2 Negative Breast Cancer\nEstimated primary comple
 tion: 10 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06207734
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498648-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT06498648)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2.\nStudy: Testing the Additio
 n of an Anti-cancer Drug\, Abemaciclib\, to the Usual Chemotherapy Treatme
 nt (Gemcitabine) for Soft Tissue Sarcoma\nEstimated primary completion: 31
  January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemac
 iclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06498648
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06835972-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT06835972)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2.\nStudy: A Study of Abemacic
 lib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC
 )\nEstimated primary completion: February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06835972
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413706-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06413706)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Glioma.\nStudy: A Study Comp
 aring Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Childre
 n and Young Adults With High-grade Glioma Following Radiotherapy\nEstimate
 d primary completion: February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06413706
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06341621-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT06341621)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Chemo
 therapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes 
 Receiving Extended Adjuvant Abemaciclib\nEstimated primary completion: 25 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemac
 iclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06341621
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06179303)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Functional Imaging in Prediction of Response to Abemacicli
 b for Advanced Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEs
 timated primary completion: 1 March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594679-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT06594679)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2.\nStudy: A Study of Nirapari
 b in Combination With Abemaciclib for Late Line Treatment of Ovarian Cance
 r (NICHOL TRIAL)\nEstimated primary completion: 20 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06594679
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05548127-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270324
DTEND;VALUE=DATE:20270325
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05548127)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: TACTIVE-U: A Study to Learn About the Study Medicine (Ve
 pdegestrant) When Given With Other Medicines in People With Advanced or Me
 tastatic Breast Cancer (Sub-Study A)\nEstimated primary completion: 24 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0554
 8127
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810544-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT06810544)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, Glioma.\nStudy: Safety and
  Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patie
 nts With Solid Tumors With MTAP Loss\nEstimated primary completion: 31 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0681
 0544
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06409390)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for 
 Breast Cancer\nEstimated primary completion: April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05696626-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT05696626)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Evaluation of Lasofoxifene Combined With Abemaciclib Compa
 red With Fulvestrant Combined With Abemaciclib in Locally Advanced or Meta
 static ER+/HER2- Breast Cancer With an ESR1 Mutation\nEstimated primary co
 mpletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05696626
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06654037-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Verzenio (Abemaciclib): Phase 1 readout est. (NCT06654037)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1.\nStudy: Testing the Addition 
 of an Anti-Cancer Drug\, Abemaciclib\, to the Usual Chemotherapy Treatment
  (5-Fluorouracil) for Metastatic\, Refractory Colorectal Cancer\nEstimated
  primary completion: 1 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06654037
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501704-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05501704)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: ETHAN - ET for Male BC\nEstimated primary completion: 1 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 01704
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04614194-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04614194)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Singl
 e Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaci
 clib\nEstimated primary completion: 15 April 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04614194
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441369-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07441369)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Abemaciclib Combined 
 With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Met
 astases Cancer\nEstimated primary completion: 30 April 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07441369
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999994-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05999994)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: A Master Protocol (LY
 900023) That Includes Several Clinical Trials of Drugs for Children and Yo
 ung Adults With Cancer\nEstimated primary completion: May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05999994
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04633239-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Verzenio (Abemaciclib): Phase 1 readout est. (NCT04633239)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1.\nStudy: Testing the Addition 
 of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer\nEstima
 ted primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04633239
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04305834-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270521
DTEND;VALUE=DATE:20270522
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04305834)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Abemaciclib and Endocrine Therapy in Older Patients With B
 reast Cancer.\nEstimated primary completion: 21 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04305834
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05113537-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05113537)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2.\nStudy: Abemaciclib Before 
 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate
  Cancer\nEstimated primary completion: 31 May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05113537
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05095207-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05095207)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Abemaciclib in Combination With Bicalutamide for Androge
 n Receptor-positive\, HER2-negative Metastatic Breast Cancer\nEstimated pr
 imary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05095207
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05774899-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05774899)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2.\nStudy: CB-103 With Either 
 Lenvatinib or Abemaciclib in Patients With NOTCH ACC\nEstimated primary co
 mpletion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05774899
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04040205-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04040205)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Abemaciclib for Bone 
 and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alterat
 ion\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04040205
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05372640-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270607
DTEND;VALUE=DATE:20270608
SUMMARY:Verzenio (Abemaciclib): Phase 1 readout est. (NCT05372640)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Testing the Safety and Efficacy of the Combination of Two 
 Anti-cancer Drugs\, ZEN003694 and Abemaciclib\, for Adult and Pediatric Pa
 tients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma\, Breas
 t Cancer and Other Solid Tumors\nEstimated primary completion: 7 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05372640
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A First-in-human Dose Escalation and Expansion Study to 
 Evaluate the Safety\, and Tolerability of AZD8421 Alone or in Combination 
 in Participants With Selected Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06188520
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735080-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05735080)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Open-Label Study to Evaluate the Safety\, Tolerability\,
  PK\, and Efficacy of INX-315 in Patients With Advanced Cancer\nEstimated 
 primary completion: July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05735080
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04923542-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT04923542)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: SRS & Abemaciclib w/wo Imlunestrant in the Management of
  HR+/HER2- Breast CA Brain Metastases\nEstimated primary completion: July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0492354
 2
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02846987-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT02846987)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Study of Abemaciclib 
 in Dedifferentiated Liposarcoma\nEstimated primary completion: July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT02846987
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03220646-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT03220646)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Abemaciclib (LY283521
 9) in Patients With Recurrent Primary Brain Tumors\nEstimated primary comp
 letion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ab
 emaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03220646
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04469764-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04469764)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Abemaciclib for the T
 reatment of Recurrent Ovarian or Endometrial Cancer\nEstimated primary com
 pletion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04469764
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05386108-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05386108)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of Abemaciclib and Elacestrant in Participants Wit
 h Brain Metastasis Due to ER+/HER-2- Breast Cancer\nEstimated primary comp
 letion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05386108
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06025747-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Verzenio (Abemaciclib): Phase 1 readout est. (NCT06025747)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1.\nStudy: A Phase 1 Study of Ne
 oadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcom
 as\nEstimated primary completion: 3 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06025747
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: The Drug Rediscovery 
 Protocol (DRUP Trial)\nEstimated primary completion: September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06366347-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06366347)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: ALPINE: Maintenance L
 etrozole/Abemaciclib\nEstimated primary completion: 1 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06366347
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03531645-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT03531645)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Fulvestrant Plus Abem
 aciclib in Women With Advanced Low Grade Serous Carcinoma\nEstimated prima
 ry completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03531645
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04862663)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastat
 ic HR+/HER2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 
 1 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abem
 aciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04862663
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06365788-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06365788)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Bical
 utamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-posi
 tive Triple-negative Breast Cancer\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063657
 88
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523857-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04523857)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: ABemacicliB or Abemaciclib and HydroxYchloroquine to Targe
 t Minimal Residual Disease in Breast Cancer\nEstimated primary completion:
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abema
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04523857
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07935317)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: A Stu
 dy of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Par
 ticipants With PIK3CA-Mutated Early Breast Cancer\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07935317
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04967521-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04967521)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3.\nStudy: SARC041: Study of Abe
 maciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposar
 coma\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04967521
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599137-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Verzenio (Abemaciclib): Phase 4 readout est. (NCT07599137)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 4\, Breast Cancer.\nStudy: Abema
 ciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07599137
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608252-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05608252)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: VS-6766+Abema+Fulv in Met HR+/HER- BC\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05608252
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT02693535)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: TAPUR: Testing the Us
 e of Food and Drug Administration (FDA) Approved Drugs That Target a Speci
 fic Abnormality in a Tumor Gene in People With Advanced Stage Cancer\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05872204-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05872204)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Abemaciclib and Letrozole in Patients With Estrogen Recept
 or-positive Rare Ovarian Cancer\nEstimated primary completion: January 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05872204
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors
 \nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in
  Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast
  Cancer\nEstimated primary completion: February 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02977780-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT02977780)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: INdividualized Screen
 ing Trial of Innovative Glioblastoma Therapy (INSIGhT)\nEstimated primary 
 completion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT02977780
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813079-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06813079)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Using Tumor Models to
  Determine Treatments\nEstimated primary completion: 17 February 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06813079
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT04931342)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: A Study Evaluating th
 e Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persi
 stent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primary compl
 etion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04931342
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04941274-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT04941274)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2.\nStudy: Abemaciclib in Pati
 ents With HIV-associated and HIV-negative Kaposi Sarcoma\nEstimated primar
 y completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04941274
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT06065748)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study to Evaluate Efficacy and Safety of Giredestrant Co
 mpared With Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With E
 R-Positive\, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant En
 docrine Therapy (pionERA Breast Cancer)\nEstimated primary completion: 20 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemacicl
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6065748
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Phase Ib/II Study to Evaluate Multiple Combination The
 rapies of FWD1802 in Patients With ER+/HER2- BC\nEstimated primary complet
 ion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abem
 aciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07002177
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT05891093)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Effic
 acy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for 
 HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)\nEstimated primar
 y completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05891093
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04565054-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04565054)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Adjuv
 ant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic Hi
 gh Risk\, HR+/HER2- EBC\nEstimated primary completion: June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04565054
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02523014-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT02523014)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Vismodegib\, FAK Inhi
 bitor GSK2256098\, Capivasertib\, and Abemaciclib in Treating Patients Wit
 h Progressive Meningiomas\nEstimated primary completion: 1 June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT02523014
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05708235-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05708235)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A PoC Study to Evaluate Treatments' Efficacy by Monitoring
  MRD Using ctDNA in HR-positive/HER2-negative EBC Population\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05708235
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062498-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT06062498)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Pati
 ents With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer\nE
 stimated primary completion: 1 July 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06062498
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112053-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07112053)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy 
 or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive\
 , HER2 Negative Breast Cancer\nEstimated primary completion: 31 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07112053
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03675893-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT03675893)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: RESOLVE: Abemaciclib 
 + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer\nEstimated 
 primary completion: 1 August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03675893
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05940493-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05940493)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Abemaciclib in Newly 
 Diagnosed Meningioma Patients\nEstimated primary completion: September 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05940493
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209449-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07209449)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: A Study of Elacestran
 t Alone or in Combination With Abemaciclib in People With Endometrial Canc
 er\nEstimated primary completion: 1 October 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07209449
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905001-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Verzenio (Abemaciclib): Phase 1 readout est. (NCT07905001)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Phase 1/1b Study of PRT13722 in Participants With Advanc
 ed HR+/HER2- Breast Cancer\nEstimated primary completion: 31 October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07905001
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06678269-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Verzenio (Abemaciclib): Phase 1 readout est. (NCT06678269)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of Abemaciclib and Radiation Therapy in People Wit
 h Metastatic Breast Cancer\nEstimated primary completion: 30 November 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06678269
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07292207-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07292207)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Abema
 ciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in
  HR+/HER2- Early Breast Cancer\nEstimated primary completion: 30 November 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0729220
 7
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832227-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07832227)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: Imlunestrant/Abemacic
 lib/Selinexor in Ovarian and Endometrial\nEstimated primary completion: 1 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemac
 iclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07832227
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04616183-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT04616183)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2.\nStudy: LY3214996 and Cetux
 imab Alone or in Combination With Abemaciclib for the Treatment of Unresec
 table or Metastatic Colorectal Cancer\nEstimated primary completion: 31 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemacic
 lib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04616183
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04750928-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT04750928)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2.\nStudy: Cyclin-Dependent Ki
 nase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Rel
 ated Atypical Neurofibromas\nEstimated primary completion: 31 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04750928
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524584-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05524584)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Anastrazole\, Fulvestrant & Abemaciclib for HR+HER2- Metas
 tatic Breast Cancer\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05524584
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05362760-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Verzenio (Abemaciclib): Phase 4 readout est. (NCT05362760)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 4\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Combination of Abemaciclib and Endocrine Therapy in Hormon
 e Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Ca
 ncer With Focus on Digital Side Effect Management\nEstimated primary compl
 etion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ab
 emaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05362760
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410559-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07410559)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Neoad
 juvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 
 2 Weeks for ER-Positive HER2-Negative Breast Cancer\nEstimated primary com
 pletion: 1 April 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07410559
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07428018-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07428018)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Pragm
 atic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in
  HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib\nEstimate
 d primary completion: 30 April 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07428018
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple T
 reatment Combinations in Participants With Breast Cancer\nEstimated primar
 y completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04802759
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605728-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07605728)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Probiotics for Abemaciclib-Induced Abdominal Discomfort.\n
 Estimated primary completion: 30 June 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07605728
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490509-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Verzenio (Abemaciclib): Phase 4 readout est. (NCT07490509)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 4\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Pharmacokinetic Model of Abemaciclib: Correlation With Sev
 ere Diarrhea as the Primary Toxicity Endpoint in Patients With Localized H
 ormone Receptor-positive Breast Cancer\nEstimated primary completion: Sept
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemacicl
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7490509
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT06380751)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Th
 erapy\, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Cami
 zestrant in HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplifie
 d)\, BRCA1\, BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary c
 ompletion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06380751
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952557-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT05952557)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: An Ad
 juvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2
 - Early Breast Cancer (CAMBRIA-2)\nEstimated primary completion: 4 March 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05952557
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191717-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07191717)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Imlun
 estrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Br
 east Cancer in Patients With Minimal Residual Disease\, MIRI Trial\nEstima
 ted primary completion: 30 April 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07191717
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monother
 apy and in Combination With Other Antineoplastic Agents in Participants Wi
 th Advanced Solid Tumors\nEstimated primary completion: July 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Verzenio (Abemaciclib): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 1/2\, HR+/HER2- Metastatic Breas
 t Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple T
 reatment Combinations in Patients With Metastatic or Locally Advanced Brea
 st Cancer\nEstimated primary completion: 30 September 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05933395-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05933395)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Genetically-informed Therapy for ER+ Breast Cancer Post-CD
 K4/6 Inhibitor\nEstimated primary completion: October 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05933395
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04584853-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT04584853)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: PreOperative Endocrine Therapy for Individualised Care Wit
 h Abemaciclib\nEstimated primary completion: October 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04584853
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06169371-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Verzenio (Abemaciclib): Phase 4 readout est. (NCT06169371)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 4\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
 \nEstimated primary completion: November 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06169371
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT01042379)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: I-SPY
  TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast
  Cancer\nEstimated primary completion: December 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340541-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20310602
DTEND;VALUE=DATE:20310603
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT07340541)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2\, Breast Cancer.\nStudy: Evolu
 tionary Clinical Trial for Novel Biomarker-Driven Therapies\nEstimated pri
 mary completion: 2 June 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/abemaciclib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07340541
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406594-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Verzenio (Abemaciclib): Phase na readout est. (NCT07406594)
DESCRIPTION:Verzenio (Abemaciclib)\, phase na\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Gut Microbiome Changes During Abemaciclib Therapy in Brea
 st Cancer\nEstimated primary completion: October 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07406594
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Verzenio (Abemaciclib): Phase 2 readout est. (NCT05159245)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 2.\nStudy: The Finnish National 
 Study to Facilitate Patient Access to Targeted Anti-cancer Drugs\nEstimate
 d primary completion: 25 November 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/abemaciclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190443-2159@assetmemo.bio
DTSTAMP:20261121T004501Z
DTSTART;VALUE=DATE:20340206
DTEND;VALUE=DATE:20340207
SUMMARY:Verzenio (Abemaciclib): Phase 3 readout est. (NCT07190443)
DESCRIPTION:Verzenio (Abemaciclib)\, phase 3\, Breast Cancer.\nStudy: Adjuv
 ant Abemaciclib for Locoregional Recurrence of HR-positive\, HER2-negative
  Breast Cancer (JCOG2313\, AURA)\nEstimated primary completion: 6 February
  2034. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abemaciclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071904
 43
URL:https://assetmemo.bio/drug/abemaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
